Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Palatability of Etrasimod Mini Tablets vs IR Tablets
NCT05956002Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2023
- Primary completion
- Jan 2024
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ponesimod in ulcerative colitis (UC) (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration at Day 1, Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity at Day 1 and 1 more. Started Sep 2023; status: completed.
02
Drugs
ponesimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05956002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956002.